Soligenix Inc (SNGX)

[drbio45]

Most of the survival benefit came from the mismatched donors, true. But there was a tremendously reduced difference in treatment failures in favor orbec at day 50 and day 80.

It was only treatment thru day 50 that showed a trend and not statistical significance. As far as the reason that more patients failed on orBec in the first 10 days, the patients were sicker in the orBec arm and the drug may not have had enough time to work.

I believe they can get passed this because in the phase 2 trial there was a clear benefit to orBec in the first 10 days. They should have included that in the article, but the FDA has that info.